MGEN Insider Trading Activity and SEC Form 4 Filings
MGEN insider trading summary
No open-market insider purchases or sales of Miragen Therapeutics, Inc. (MGEN) have been reported on SEC Form 4 in the past 12 months.
Latest MGEN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 13, 2020 | Logos Global Master Fund LP | 10% Owner | Buy | $1.9M (126,667 @ $14.84) |
| Nov 9, 2020 | Logos Global Master Fund LP | 10% Owner | Buy | $116K (100,000 @ $1.16) |
| Nov 9, 2020 | Logos Global Master Fund LP | 10% Owner | Buy | $274K (250,000 @ $1.10) |
| Oct 11, 2018 | Thomas E. Hughes | Director | Buy | $48K (10,000 @ $4.77) |
| Feb 13, 2018 | Adam Scott Levy | Chief Business Officer | Buy | $50K (9,090 @ $5.50) |
| Feb 13, 2018 | Bruce Booth | Director | Buy | $3.0M (545,454 @ $5.50) |
| Dec 20, 2017 | Thomas E. Hughes | Director | Sell | $96K (12,000 @ $8.00) |
| Jun 22, 2017 | Adam Scott Levy | Chief Business Officer | Buy | $2K (200 @ $7.55) |
| Mar 10, 2017 | Kyle Lefkoff | Director | Sell | $47K (3,300 @ $14.31) |
| Mar 9, 2017 | Kyle Lefkoff | Director | Sell | $36K (2,500 @ $14.38) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.